ANZCTR search results

Aims: To conduct a first-ever long-term (10-15 years) follow-up of individuals at risk of Alzheimer’s disease (AD) who participated in a 6-month physical activity intervention versus usual-care to asses the effects on cognition, mental and physical health, and quality of life. Hypothesis: We hypothesise that the group who undertook the physical activity intervention will have better mental and physical outcomes and a lower rates of Alzheimer’s disease and lower use of health services. Methods: Individuals recruited into the original trial were re-contacted and invited to take part in this follow-up. In Stage 1 of the Follow-up study invitations were posted with 69 re-interviewed and data collected. In Stage 2 we propose to access information from the WA Department of Health data linkage service for those not withdrawing from the original study and those opting out of the follow-up interview to obtain information from several linked health agency databases.

Comparison of bronchial mucus transport velocity in patients having either sevoflurane or desflurane based anaesthesia.

The study followed the health outcomes of 124 Independent Living Unit residents aged 75 years or over and living alone to see if health assessments and early basic interventions had an impact on their health and well being. If required, interventions included health information, specialist referrals, and home help. Residents were linked to a community nurse, who provided low intensity case management by phone every three months. Half of the participants participated in the early intervention experimental model, while the remainder received their usual community care. At the end of the 12 month study period, those involved in the experiment had a higher level of satisfaction with community care, but more time was needed to see if there were other detectable health outcomes. We found previously unidentified needs among 66% of the experimental group, and throughout the course of the study most of those needs were resolved. However, no other benefits from the program were detected after one year in terms of health perception, functional ability, psychosocial status, health resource utilisation and mortality. This was consistent with many other similar studies.

Intraoperative bronchoscopic assessment of bronchial mucus transport velocity in patients having either an anaesthesia with morphine/propofol or remifentanil/propofol.

Phase 1 This is a trial of an anti-cancer treatment known as BDCA-BDC-01 which is a preparation of blood dendritic cells (BDC-1 type) loaded with antigens. The treatment is for immune therapy of distant secondary cancer (metastases) of the prostate when this no longer responds to hormone treatment (hormone-refractory). Who is it for? You can take part in this trial if you have distant secondary prostate cancer which has not responded to androgen deprivation therapy (therapy to reduce levels of the hormone testosterone in your body). Trial details Participants receive injections either under the skin or intravenously with a BDC-1 blood dendritic cell preparation which is loaded with special proteins (antigens that prompt the formation of antibodies). This happens once a month for 3 months. The trial aims to induce an immune response against the cancer and assess the safety and effectiveness of this treatment. Dendritic cells are important immune cells which are normally present in the human body. BDC-1 dendritic cells are a type of dendritic cell. Dendritic cells can be prepared with special proteins from the prostate cancer to enhance the immune response. The standard treatment for metastatic prostate cancer that is not responding to androgen deprivation is chemotherapy.